bluebird bio (BLUE)
(Real Time Quote from BATS)
$0.50 USD
+0.01 (1.07%)
Updated Oct 11, 2024 11:36 AM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BLUE 0.50 +0.01(1.07%)
Will BLUE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLUE
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Other News for BLUE
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Maintaining Hold on Bluebird Bio Amid Skysona Safety Concerns and Financial Constraints
7 children given bluebird's Skysona developed blood cancer: study
Top 10 most shorted stocks on Wall Street
Bluebird Bio (BLUE) Stock Dips Amid Market Volatility